









		Trials Conducted to Date or in Progress				Marketed
		Preclinical	Phase 1	Phase 2	Phase 3	
PROPHYLACTIC VACCINES						
Norovirus ¹	Bivalent					
Seasonal Influenza ²	Monovalent					
	Quadrivalent					
Influenza	Universal ³	 				
COVID-19						
RSV ⁴						
THERAPEUTIC VACCINES						
HPV ⁵	HPV, cervical dysplasia and/or cancer					

- 1) Bivalent Phase 1 demonstrated IgA ASC response rates of 90 – 93% for GII.4 and 78 – 86% for GI.1
- 2) Monovalent H1 flu vaccine completed phase 2 Proof of Concept efficacy study.
- 3) Janssen collaboration with an option to negotiate an exclusive license.
- 4) RSV program to be partnered with new antigen partner.
- 5) HPV therapeutic pre-IND feedback received.